Placebo News and Research

RSS

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

AstraZeneca today presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies.

22 May 2013

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of tiotropium in asthma. These data were presented at the American Thoracic Society International Conference in Philadelphia, Pennsylvania.

22 May 2013

Ongoing clinical study to evaluate benefits of high-dose simvastatin for patients with SAH

Can treatment with high doses of a cholesterol-lowering statin drug improve outcomes for patients with stroke caused by rupture and bleeding of brain aneurysms? An ongoing clinical trial will soon find out, according to an article in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

22 May 2013

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience, Inc., a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic M, has "robust efficacy".

22 May 2013

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Extended use of a common antibiotic may prolong the time between hospitalizations for patients suffering from chronic obstructive pulmonary disease, according to a post-hoc analysis of a multicenter study which compared the hospitalization rates of patients treated with a 12-month course of azithromycin to the rates of those treated with placebo.

22 May 2013

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Grifols, S.A. and Aradigm Corporation today announced the signing of an exclusive, worldwide license for Aradigm's proprietary formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis.

21 May 2013

Biogen Idec seeks FDA BLA approval for PLEGRIDY to treat multiple sclerosis

Today Biogen Idec announced it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of PLEGRIDY (peginterferon beta-1a), the company's pegylated subcutaneous injectable candidate for relapsing forms of multiple sclerosis (RMS).

21 May 2013

Research explores pharmaceutical advances for IBS, hepatitis C

Research presented at Digestive Disease Week explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea and hepatitis C.

21 May 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort, Inc. announced today top-line results from its pivotal Phase 3 clinical trial of arbaclofen placarbil for the treatment of patients with spasticity due to multiple sclerosis.

20 May 2013

Study shows treatment of sleep apnea in patients with prediabetes improves blood sugar levels

Optimal treatment of sleep apnea in patients with prediabetes improves blood sugar (glucose) levels and thus can reduce cardiometabolic risk, according to a study to be presented at the ATS 2013 International Conference in Philadelphia.

20 May 2013

Patients with treatment-resistant depression benefit from ketamine

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai.

20 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Research presented at Digestive Disease Week explores new methods for managing digestive health through diet and lifestyle.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Non-invasive brain stimulation techniques improve memory

Non-invasive brain stimulation techniques aimed at mental and neurological conditions include transcranial magnetic stimulation for depression, and transcranial direct current (electrical) stimulation, shown to improve memory.

20 May 2013

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

UCB today announced data from a double-blind, placebo-controlled study that found that Neupro (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure elevations associated with periodic limb movements during sleep and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome/Willis-Ekbom disease.

18 May 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

UHCMC researchers to present data on patient and physician barriers to clinical trials

Researchers from University Hospitals Case Medical Center's Seidman Cancer Center will present findings from two studies evaluating new technologies designed to address common barriers to patient enrollment in clinical trials.

16 May 2013

Placebo News and Research

Naloxegol meets primary and secondary endpoints in two pivotal Phase III studies

Boehringer Ingelheim's tiotropium shows promising results in patients with severe persistent asthma

Ongoing clinical study to evaluate benefits of high-dose simvastatin for patients with SAH

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

Study: Extended azithromycin therapy may offer significant benefits to COPD patients

Grifols signs worldwide licensing agreement for Aradigm's Pulmaquin

Biogen Idec seeks FDA BLA approval for PLEGRIDY to treat multiple sclerosis

Research explores pharmaceutical advances for IBS, hepatitis C

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

Study shows treatment of sleep apnea in patients with prediabetes improves blood sugar levels

Patients with treatment-resistant depression benefit from ketamine

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Non-invasive brain stimulation techniques improve memory

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

Newer class of diabetes medications may also improve cardiovascular health, researchers report

UHCMC researchers to present data on patient and physician barriers to clinical trials

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News